Navigation Links
Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
Date:11/15/2011

RIDGEFIELD, Conn., Nov. 15, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals announced today that it has made more than $350 million worth of capital investments throughout its U.S. operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities. Privately-held, family-owned Boehringer Ingelheim continues to grow by improving its state-of-the-art facilities and enhancing its research, development and manufacturing capabilities.

The latest investment is a 72,000 square-foot research and development facility at the company's U.S. headquarters in Ridgefield, Connecticut. When complete the $65 million facility will handle production of active pharmaceutical ingredients used in early development activities. Products developed here, if approved, move on to Boehringer Ingelheim's full-scale R&D facilities in Ohio and Virginia, as well as Germany and Italy.

"This new R&D facility will help generate life-saving drugs and improve the health of countless people. As new drug invention continues to be in short supply, I am pleased that Boehringer Ingelheim is expanding this critical work right here in Connecticut, helping to grow both jobs and healthcare," said U.S. Senator Richard Blumenthal (D-Conn.).

"The ground-breaking research that will take place at this facility will put successful medical ideas to work for millions of additional patients, all while creating jobs here in Connecticut," Congressman Jim Himes (D-Conn.) said. "Congratulations to Boehringer Ingelheim on this new chapter. I look forward to our continued work together."

Other investment announcements by Boehringer Ingelheim in 2011 include:

In August, the company announced its investment in a new drug safety assessment building in Ridgefield, Conn. The $42 million project is scheduled to be completed in 2013 and will provide space for non-clinical safety studies.

The company's U.S. animal health business, Boehringer Ingelheim Vetmedica, Inc., this summer dedicated its new $89 million vaccine research facility in Sioux Center, Iowa, one of three special vaccine research buildings it will build there. The company also announced a $100 million expansion of its biological manufacturing facility in St. Joseph's, Missouri.

In September, Boehringer Ingelheim Roxane, Inc., opened a new $50 million High Containment Operations facility in Columbus, Ohio in order to meet a growing market demand for high potency and oncology products.  The building uses state-of-the-art technology to develop and manufacture differentiated high potency oral solid tablets and capsules in support of Roxane Laboratories', Inc. rapidly growing multisource business.  

In addition to these capital investments, Boehringer Ingelheim gained a presence on the West Coast with the acquisition in March of Boehringer Ingelheim Fremont, Inc. The facility, acquired from Amgen, manufactures biological medicines, and consists of more than 300,000 square feet for laboratories, manufacturing and process development suitable for clinical and market supplies.

"These are exciting projects; ones that increase Boehringer Ingelheim's research and development capabilities and reinforce our commitment to growth and innovation in the U.S.," said J. Martin Carroll, President and CEO of Boehringer Ingelheim's U.S. operations. "Through these investments we are improving our ability to research, develop and manufacture the medicines of tomorrow and in doing so fulfilling our promise to bring more health to patients and their families."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
2. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
3. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
4. Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
5. Boehringer Ingelheim and Ashokas Changemakers Launch "Making More Health" Competition
6. Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"
7. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
8. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
9. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
10. Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
11. Boehringer Ingelheim to Purchase Amgens Fremont (USA) Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):